AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-53. (Canceled)

54. (Currently amended) A method for reducing T cell responsiveness *in vivo* to an autoantigen expressing cell, which method comprises ~~comprising~~ administering to a subject in need of such treatment

(i) an antigen presenting cell that presents an autoantigen ~~expressing cell~~;

(ii) ~~a gp39 antagonist selected from the group consisting of~~ an anti-gp39 antibody~~,~~ ~~or an anti-gp39 antibody fragment that binds gp39, soluble CD40, and soluble CD40 fusion proteins~~;

wherein said gp39 ~~antagonist~~ antibody or fragment is administered prior, concurrent and/or subsequent to administration of said ~~autoantigen expressing cells~~ antigen-presenting cell, and said gp39 antagonist is administered in an amount effective to reduce T cell responses to said ~~autoantigen expressing cells~~ antigen-presenting cell.

55. (Currently amended) The method of claim 54 wherein said antigen ~~expressing~~ presenting cell is selected from the group consisting of B lymphocytes, monocytes, dendritic cells, Langerhans' cells, keratinocytes, endothelial cells, astrocytes, fibroblasts and oligodendrocytes.

56. (Previously presented) The method of claim 54 wherein the antigen presenting cell is a B lymphocyte.

57. (Canceled)

58. (Currently amended) The method of claim 54 wherein the antigen presenting cell is a Langerhans cell.

59. (Previously presented) The method of claim 54 wherein the antigen presenting cell is a lymphoid cell.

60. (Previously presented) The method of claim 54 wherein the gp39 antagonist is an anti-human gp39 antibody.

61. (Previously presented) The method of claim 60 wherein said antibody is a humanized anti-human gp39 antibody.

62. (Previously presented) The method of claim 60 wherein said antibody is a chimeric anti-human gp39 antibody containing human constant regions.

63. (Currently amended) The method of claim ~~54~~ 56, wherein the antigen presenting cell is a peripheral blood activated B lymphocyte.

New claims:

64. (New) The method of claim 54, wherein the antigen presenting cell is a bone marrow activated B lymphocyte.

65. (New) The method of claim 54, wherein the antigen-presenting cell is a dendritic cell.

66. (New) The method of claim 54, wherein the anti-gp39 antibody is a monoclonal antibody.

67. (New) The method of claim 66, wherein the anti-gp39 antibody is MR1, an antibody that is produced by the hybridoma having ATCC Accession No. HB 11048.

68. (New) The method of claim 54, wherein the anti-gp39 antibody is a chimeric anti-human gp39 antibody containing human constant regions.